SCHEMBL4105332

SCHEMBL4105332

Nc1c(C(=O)O)sc2nc3c(c(-c4cccs4)c12)CNC3

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.61
HPGD P15428 6/20 0.61
TDP1 Q9NUW8 2/20 0.61
HTT P42858 2/20 0.61
LMNA P02545 2/20 0.60
KDM4E B2RXH2 6/20 0.57
NPSR1 Q6W5P4 5/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
GAA P10253 1/20 0.57
MAPT P10636 9/20 0.52
KMT2A Q03164 9/20 0.47
POLB P06746 3/20 0.47
IKBKB O14920 1/20 0.44
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
MEN1 O00255 7/20 0.43
LIMK1 P53667 1/20 0.42
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
BRCA1 P38398 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115555 0.92 ALDH1A1 (0.63) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL5958465 0.91 ALDH1A1 (0.74) ALDH1A1HPGDTDP1HTTLMNA
Hydrochloric Acid SCHEMBL4104360 0.90 ALDH1A1 (0.72) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL4106730 0.83 ALDH1A1 (0.74) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL14955157 0.80 MAPT (0.79) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL4112923 0.76 MAPT (0.58) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL4113110 0.76 ALDH1A1 (0.56) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL13941637 0.76 ALDH1A1 (0.96) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL429207 0.76 ALDH1A1 (1.00) ALDH1A1HPGDTDP1HTTLMNA
SCHEMBL13991623 0.74 ALDH1A1 (0.71) ALDH1A1HPGDTDP1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090029983-A1 NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY VALEANT RESEARCH & DEVELOPMENT (US) 2009-01-29 US disclosed
US-7465742-B2 Heterocyclic compounds having anti-HBV activity VRX HOLDCO LLC 2008-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029983-A1 NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY HCCS, HAVCR2, HMBS ALDH1A1 3227/4885HPGD 58/4885TDP1 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.